$2.64
2.58% yesterday
Nasdaq, Oct 30, 09:00 pm CET
ISIN
US0345691036
Symbol
ANEB

Anebulo Pharmaceuticals Inc Stock price

$2.64
+0.14 5.60% 1M
+1.43 118.18% 6M
+0.96 57.14% YTD
+0.79 42.70% 1Y
+0.23 9.54% 3Y
-4.36 62.29% 5Y
-4.36 62.29% 10Y
-4.36 62.29% 20Y
Nasdaq, Closing price Thu, Oct 30 2025
-0.07 2.58%
ISIN
US0345691036
Symbol
ANEB
Industry

Key metrics

Basic
Market capitalization
$108.5m
Enterprise Value
$96.8m
Net debt
positive
Cash
$11.6m
Shares outstanding
41.1m
Valuation (TTM | estimate)
P/E
negative | negative
P/S
- | -
EV/Sales
- | -
EV/FCF
negative
P/B
9.3
Financial Health
Equity Ratio
96.0%
Return on Equity
-72.8%
ROCE
-79.1%
ROIC
-
Debt/Equity
0.0
Financials (TTM | estimate)
Revenue
$0.0 | $0.0
EBITDA
- | -
EBIT
$-9.2m | $-14.8m
Net Income
$-8.5m | $-20.1m
Free Cash Flow
$-6.4m
Growth (TTM | estimate)
Revenue
- | -
EBITDA
- | -
EBIT
-11.1% | -61.0%
Net Income
-3.4% | -137.2%
Free Cash Flow
21.5%
Margin (TTM | estimate)
Gross
-
EBITDA
- | -
EBIT
-
Net
- | -
Free Cash Flow
-
More
EPS
$-0.2
FCF per Share
$-0.2
Short interest
2.6%
Employees
3
Rev per Employee
$0.0
Show more

Is Anebulo Pharmaceuticals Inc a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 7,029 stocks worldwide.

Anebulo Pharmaceuticals Inc Stock Analysis

Unlock Scores for Free

Analyst Opinions

6 Analysts have issued a Anebulo Pharmaceuticals Inc forecast:

3x Hold
50%
3x Sell
50%

Analyst Opinions

6 Analysts have issued a Anebulo Pharmaceuticals Inc forecast:

Hold
50%
Sell
50%

Financial data from Anebulo Pharmaceuticals Inc

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Jun '25
+/-
%
- -
-
100%
- Direct Costs - -
-
-
- -
-
-
- Selling and Administrative Expenses 4.92 4.92
3% 3%
-
- Research and Development Expense 4.30 4.30
21% 21%
-
- -
-
-
- Depreciation and Amortization - -
-
-
EBIT (Operating Income) EBIT -9.22 -9.22
11% 11%
-
Net Profit -8.48 -8.48
3% 3%
-

In millions USD.

Don't miss a Thing! We will send you all news about Anebulo Pharmaceuticals Inc directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Anebulo Pharmaceuticals Inc Stock News

Neutral
Business Wire
about one month ago
AUSTIN, Texas--(BUSINESS WIRE)--Anebulo Pharmaceuticals Reports Fourth Quarter and Fiscal Year 2025 Financial Results and Recent Updates.
Neutral
Business Wire
about one month ago
AUSTIN, Texas--(BUSINESS WIRE)--Anebulo Pharmaceuticals, Inc. (Nasdaq: ANEB), a clinical-stage biopharmaceutical company developing novel solutions for people suffering from acute cannabinoid-induced toxicities (the “Company” or “Anebulo”), today announces the first subjects dosed in its Phase 1 single ascending dose (“SAD”) study of intravenous (IV) selonabant in healthy young adults. The stud...
Neutral
Business Wire
about 2 months ago
AUSTIN, Texas--(BUSINESS WIRE)--Anebulo Pharmaceuticals Announces Update on Going Private Transaction and Strategic Alternatives.
More Anebulo Pharmaceuticals Inc News

Company Profile

Anebulo Pharmaceuticals, Inc. engages in the provision of pharmaceutical services. The firm product candidate is ANEB-001, a potent, small molecule cannabinoid receptor antagonist, designed to address the unmet medical need for a specific antidote for cannabinoid overdose. The company was founded by Lawyer Joseph F on April 23, 2020 and is headquartered in Lakeway, TX.

Head office United States
CEO Richard Cunningham
Employees 3
Founded 2020
Website www.anebulo.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today